EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Plasma Concentrations of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Different Degrees of Obesity

Danilo Menichelli, Arianna Pannunzio, Erminia Baldacci, Vittoria Cammisotto, Valentina Castellani, Rosaria Mormile, Ilaria Maria Palumbo, Antonio Chistolini, Francesco Violi, Job Harenberg, Daniele Pastori iD, Pasquale Pignatelli

Clinical Pharmacokinetics · 2025

DOI: 10.1007/s40262-025-01474-8 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Pharmacokinetics, 2025. Verfasst von Danilo Menichelli und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Surgical Specialties and Organ Transplantation "Paride Stefanini", Sapienza University of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Atrial Fibrillation, Obesity, Factor Xa Inhibitors, Anticoagulants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Università degli Studi di Roma La Sapienza.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Atrial fibrillation (AF) has multiple cardio-metabolic comorbidities, including obesity. The use of direct oral anticoagulants (DOACs) in patients with AF and obesity is still uncertain owing to the concern of possible ineffective DOAC plasma concentration. We evaluated the peak and trough plasma concentrations of DOACs in AF patients with different degrees of obesity. METHODS: Observational single-center study including patients with obesity and AF, between April 2022 and April 2024. Obesity was defined as body mass index (BMI) ≥ 30.0 kg/m2. The 2-hour peak and trough DOAC plasma concentrations were assessed. Intake of DOAC was verified on site. Multivariable logistic regression analysis was used to assess the odds ratio (OR) and 95% confidence interval (95% CI) of factors associated with below-range trough concentration (BRTC) and below-range peak concentration (BRPC). RESULTS: In total, 160 patients (33.8% women) with a mean age of 73.2 ± 9.1 years were included. The median BMI was 32.3 kg/m2. DOACs prescribed were apixaban (46.8%), rivaroxaban (21.8%), dabigatran (16.4%), and edoxaban (15.0%); 18.1% and 14.4% had BRTC and BRPC concentrations, respectively. Patients with BRTC were more frequently treated with edoxaban and dabigatran and had a higher BMI. On multivariable logistic regression analysis, dabigatran [hazard ratio (HR) 3.039, 95% CI 1.155-7.999, p = 0.024) and BMI ≥ II class (OR 2.625, 95% CI 1.087-6.335, p = 0.032] were associated with BRTC. Dabigatran (OR 4.296, 95% CI 1.523-12.120, p = 0.006) and apixaban (OR 0.277, 95% CI 0.096-0.802, p = 0.018) were directly and inversely associated with BRPC, respectively. CONCLUSIONS: A nonnegligible proportion of patients with obesity and AF have below-range plasma concentrations of DOACs. Assessment of DOAC plasma concentration in obesity class ≥ II may be useful in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationObesityFactor Xa InhibitorsAnticoagulantsHumansFemaleMaleAgedAdministration, OralAged, 80 and overMiddle AgedBody Mass IndexDabigatranPyrazolesPyridonesRivaroxabanPyridinesThiazoles

Substanzen

apixabanFactor Xa InhibitorsDabigatranPyrazolesPyridonesAnticoagulantsRivaroxabanedoxabanPyridinesThiazoles

Autor:innen und Institutionen

  • Department of General Surgery, Surgical Specialties and Organ Transplantation "Paride Stefanini", Sapienza University of Rome, Rome, Italy.
  • Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
  • Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Ruprecht Karls University of Heidelberg, Heidelberg, Germany.
  • Department of General Surgery, Surgical Specialties and Organ Transplantation "Paride Stefanini", Sapienza University of Rome, Rome, Italy. daniele.pastori@uniroma1.it.
  • Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy. daniele.pastori@uniroma1.it.

ORCID-Profile: Daniele Pastori

Förderung

  • Università degli Studi di Roma La Sapienza

Zitieren

APA

Menichelli, D., Pannunzio, A., Baldacci, E., Cammisotto, V., Castellani, V., Mormile, R., Palumbo, I. M., Chistolini, A., Violi, F., Harenberg, J., Pastori, D., & Pignatelli, P. (2025). Plasma Concentrations of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Different Degrees of Obesity. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-025-01474-8

Vancouver

Menichelli D, Pannunzio A, Baldacci E, Cammisotto V, Castellani V, Mormile R, et al. Plasma Concentrations of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Different Degrees of Obesity. Clinical Pharmacokinetics. 2025. doi:10.1007/s40262-025-01474-8

BibTeX
@article{Menichelli2025,
  author = {Menichelli, Danilo and Pannunzio, Arianna and Baldacci, Erminia and Cammisotto, Vittoria and Castellani, Valentina and Mormile, Rosaria and Palumbo, Ilaria Maria and Chistolini, Antonio and Violi, Francesco and Harenberg, Job and Pastori, Daniele and Pignatelli, Pasquale},
  title = {Plasma Concentrations of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Different Degrees of Obesity},
  journal = {Clinical Pharmacokinetics},
  year = {2025},
  doi = {10.1007/s40262-025-01474-8}
}
Kostenlos starten →